| Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease (NCT01699412) | Grupo de Estudos Multicentricos em Onco-Hematologia | 2008-08-01 |
| A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation (NCT00670423) | Jennifer E. Schwartz | 2008-05-16 |
| Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease (NCT00632658) | Ann & Robert H Lurie Children's Hospital of Chicago | 2008-01-01 |
| Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (NCT00548717) | Dana-Farber Cancer Institute | 2007-10-01 |
| Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease (NCT00314483) | Christian Medical College, Vellore, India | 2007-06-01 |
| Rituximab for GVHD (NCT00578591) | Baylor College of Medicine | 2007-06-01 |
| Thymoglobulin (ATG) Dose Finding Study (NCT00409695) | M.D. Anderson Cancer Center | 2006-12-01 |
| Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease (NCT00391170) | National Heart, Lung, and Blood Institute (NHLBI) | 2006-11-24 |
| A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease (NCT00350545) | Stanford University | 2006-08-01 |
| Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD (NCT00574470) | University of Iowa | 2006-01-01 |
| Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD) (NCT00248365) | Kiadis Pharma | 2005-11-01 |
| Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease (NCT00388362) | Stanford University | 2005-11-01 |
| Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus (NCT00117702) | Technische Universität Dresden | 2005-10-01 |
| Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) (NCT00224874) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-09-01 |
| A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients (NCT00195429) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-08-01 |
| Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation (NCT00207792) | Centre National de Greffe de Moelle Osseuse | 2005-07-01 |
| Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) (NCT00136903) | Mesoblast, Inc. | 2005-04-27 |
| Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants (NCT00106925) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-04-22 |
| Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation (NCT00130754) | Hadassah Medical Organization | 2005-02-01 |
| Study Evaluating Sirolimus in Kidney Transplant Recipients. (NCT00167947) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-01-01 |
| Study Evaluating Sirolimus in Kidney Transplant Recipients (NCT00195273) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-11-01 |
| Cyclosporine Implant for Ocular Graft-Versus-Host Disease (NCT00102583) | National Eye Institute (NEI) | 2004-10-14 |
| A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension- (NCT00189748) | Astellas Pharma Inc | 2004-08-01 |
| Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (NCT00563108) | Hospital Authority, Hong Kong | 2004-06-01 |
| Study Evaluating Sirolimus in Kidney Transplant Recipients in India (NCT00195481) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-04-01 |
| Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus (NCT00195468) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-03-01 |
| Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children (NCT00144430) | Ann & Robert H Lurie Children's Hospital of Chicago | 2004-01-01 |
| Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation (NCT00563589) | Hospital Authority, Hong Kong | 2003-08-01 |
| Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (NCT00179075) | Vanderbilt University | 2003-04-01 |
| Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (NCT00179049) | Vanderbilt University | 2003-04-01 |
| Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) (NCT00655343) | Neovii Biotech | 2003-02-01 |
| Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease (NCT00048789) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-11-04 |
| Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease (NCT00032292) | Facet Biotech | 2002-03-01 |
| Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease (NCT00032279) | Fred Hutchinson Cancer Center | 2002-03-01 |
| Blood and Marrow Transplant Clinical Research Network (NCT00023530) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-09-01 |
| Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells (NCT00023491) | National Institute of Dental and Craniofacial Research (NIDCR) | 2001-09-01 |
| Keratinocyte Growth Factor to Prevent Acute GVHD (NCT00031148) | FDA Office of Orphan Products Development | 2001-09-01 |
| Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD (NCT00233896) | Enteron Pharmaceuticals | 2001-07-01 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |
| Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation (NCT00128739) | Rafa Laboratories | 2001-01-01 |
| Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD) (NCT00146978) | Hadassah Medical Organization | 2000-12-01 |
| Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia (NCT00001144) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-10-01 |
| Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease (NCT00035880) | Abgenix | 1999-10-01 |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (NCT00001830) | National Cancer Institute (NCI) | 1999-07-20 |
| The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers (NCT00001873) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-02-22 |
| Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease (NCT00001872) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-02-02 |
| Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease (NCT00186667) | Stanford University | 1999-01-01 |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies (NCT00001748) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults (NCT00001637) | National Heart, Lung, and Blood Institute (NHLBI) | 1997-09-29 |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia (NCT00001623) | National Heart, Lung, and Blood Institute (NHLBI) | 1997-03-27 |
| Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation (NCT00001561) | National Cancer Institute (NCI) | 1996-11-01 |
| T-Cell Depletion in Unrelated Donor Marrow Transplantation (NCT00000591) | National Heart, Lung, and Blood Institute (NHLBI) | 1993-11-01 |
| Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) (NCT03172455) | Impatients N.V. trading as myTomorrows | |
| Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients (NCT00044720) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD (NCT00759018) | Mesoblast, Inc. | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease (NCT00228839) | Emory University | |
| Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients (NCT00037531) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients (NCT00189761) | Astellas Pharma Inc | |
| High Dose Chemotherapy and Autologous Transplant for Breast Cancer (NCT00186641) | Stanford University | |